Inhibition of human periodontal prostaglandin E2 synthesis with selected agents.
Considerable evidence has demonstrated the importance of PGE2 synthesis in the pathogenesis of periodontal disease. Although various cyclooxygenase inhibitors have been known to block periodontal PGE2 synthesis and prevent disease progression in animal models, there are few reports comparing relative efficacies of various inhibitors of arachidonic acid (ARA) metabolism. We have developed a sensitive in vitro assay to measure PGE2 synthesis in periodontal tissues. The apparent IC50 values (i.e. the concentration of drug which causes 50% inhibition of maximum PGE2 synthesis) have been determined for a series of arachidonic acid analogues as well as competitive and non-competitive cyclooxygenase inhibitors. Periodontal tissue homogenates were incubated in the presence of 3H-arachidonic acid for 45 min at 37 degrees C. Inhibitors were tested at 10(-10)-10(-4) M and at zero concentration to measure conversion of 3H-arachidonate to 3H-PGE2. Log or half log dilutions of inhibitors were tested in triplicate for each assay. Radiolabeled PGE2 was extracted from homogenates, purified by reverse phase chromatography and quantitated by double antibody capture. RIA was performed on each homogenate to determine the amount of endogenous unlabeled PGE2 present in the sample to correct for antibody capture recovery. The apparent IC50 values were determined for each drug by averaging two or more replicate assays. Specific total enzymatic activity of periodontal tissue homogenates was typically 5-11 pg PGE2/min/mg tissue.(ABSTRACT TRUNCATED AT 250 WORDS)
Offenbacher
S
S
Department of Periodontology, Emory University School of Postgraduate Dentistry, Atlanta, Georgia 30322.
Odle
B M
BM
Green
M D
MD
Mayambala
C S
CS
Smith
M A
MA
Fritz
M E
ME
van Dyke
T E
TE
Yeh
K C
KC
Sena
F J
FJ
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D005480:Flurbiprofen / Q000494:pharmacology; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D007660:Ketoprofen / Q000494:pharmacology; D008469:Meclofenamic Acid / Q000494:pharmacology; D009288:Naproxen / Q000494:pharmacology; D010518:Periodontitis / Q000378:metabolism*; D010519:Periodontium / Q000187:drug effects / Q000378:metabolism*; D014810:Vitamin E / Q000494:pharmacology
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D014810:Vitamin E; D016718:Arachidonic Acid; D008469:Meclofenamic Acid; D009288:Naproxen; D005480:Flurbiprofen; D007660:Ketoprofen; D015118:Eicosapentaenoic Acid; D015232:Dinoprostone; D007052:Ibuprofen